Telios Pharmaceuticals
Executive Summary
Raises additional $5.3 mil. through private placement with European venture capitalists. Financing came from Scandinavia firm A.S. Industriforsikring and from Hambrecht & Quist Life Science Ventures, Hambrecht & Quist London, Delphi BioInvestments, Technology Funding Partners III, Ventana Growth Fund, Cabanco Fondkommission and Elf Technology. Telios has raised $22 mil. to date in addition to support received from Ono.
You may also be interested in...
ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
Small Firms Get Year Reprieve From Compliance With US FDA’s Supplement Facts Label Changes
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: